The SCHOTT Pharma India name change took effect on 28 October 2026, when SCHOTT Poonawalla Private Limited became SCHOTT Pharma India Private Limited. The company says the move aligns its Indian business more closely with the global pharmaceutical packaging and drug-delivery group and is limited to the name. Ownership, management, employees, operations, products, services and customer commitments remain unchanged, according to the company announcement. This article explains what the SCHOTT Pharma India name change means for customers, suppliers and readers who track pharmaceutical packaging in India.
Key takeaways from the SCHOTT Pharma India name change
- SCHOTT Poonawalla Private Limited is now SCHOTT Pharma India Private Limited, effective 28 October 2026.
- The company says ownership, management, employees, strategy, operations, products, services and customer commitments are unchanged.
- SCHOTT Pharma AG and Co. KGaA is described as the major shareholder; the announcement quotes its chief executive, Dr Christian Mias.
- The Indian business makes pharmaceutical vials, and glass pre-fillable syringes and cartridges, and says capacity expansions are under way.
- Plant locations, employee numbers and financial figures were not disclosed.
What the SCHOTT Pharma India name change covers
The announcement describes a rename and nothing more. The legal entity, its people and its customer relationships continue, only under a new name that matches the SCHOTT Pharma brand used worldwide. The company says the new name better reflects the Indian unit’s place in the global network. We have relied on the company’s own statement and have not seen the updated registration documents, which would normally be recorded with the corporate registry. The group’s global site is schott-pharma.com.
What Indian leadership said about the SCHOTT Pharma India name change
Roy Joseph, chief executive and managing director of SCHOTT Pharma India, said the company will build on its capabilities, deepen partnerships with pharmaceutical and biotech firms and keep its focus on customers and the safe delivery of therapies. Dr Christian Mias said the new name reinforces the strategic partnership and India’s role as a key pharmaceutical hub. These are company statements, and the announcement does not add detail on strategy or investment.
Products behind the SCHOTT Pharma India name change
The company lists pharmaceutical vials, glass pre-fillable syringes and cartridges, and sterile formats. It says the products serve biologics, biosimilars, GLP-1 treatments and other injectables, and that it is the only manufacturer of glass pre-fillable syringes and sterile formats in India. That claim comes from the company, and we have not verified it independently. A pre-fillable syringe is delivered to the drugmaker already shaped for filling, which can reduce handling steps compared with filling vials and drawing doses later.
What customers and suppliers should check after the SCHOTT Pharma India name change
For most business partners, a rename means updating records rather than changing relationships. Procurement teams commonly update vendor master data, contracts, quality agreements and invoices to show the new legal name, and confirm that tax and banking details remain the same. The announcement does not give specific instructions to customers, so anyone with a supply agreement should ask the company directly. These are general practices and not company guidance.
Questions the SCHOTT Pharma India name change raises for drugmakers
Quality and regulatory teams may have more detailed questions than procurement. Will certificates, audit reports and drug master file references be reissued under the new name, and when? Do packaging specifications, batch numbering or labelling change at all? Will the contact points for technical support remain the same people? Does the rename affect any open change-control agreements with customers? The company says operations and products are unchanged, which suggests the answers are reassuring, but the announcement does not spell out the paperwork. Drugmakers should confirm these points in writing with their account teams, because regulators expect supplier information in filings to be accurate and current.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Pharmaceutical Packaging Market report values the global market at USD 121.7 billion in 2022 and projects USD 352.5 billion by 2032, a CAGR of 11.4% from 2023 to 2032. It puts North America at 38% of the 2022 market and Asia Pacific as the fastest-growing region at a CAGR of 13%. Acumen’s Dual Chamber Prefilled Syringes Market report, which covers a narrower product, values that segment at USD 162.2 million in 2023 and USD 323.7 million by 2032, a CAGR of 8.1% for 2024 to 2032, with glass at 52% of material. Both are global estimates and say nothing specific about SCHOTT Pharma India. See our Pharmaceutical section.
Timeline of the SCHOTT Pharma India name change
- 28 October 2026: SCHOTT Poonawalla becomes SCHOTT Pharma India.
- Ongoing: capacity expansions for glass pre-fillable syringes and cartridges, as stated by the company.
General background: why packaging matters for injectables
Injectable medicines, especially biologics, need containers that protect the drug, stay sterile and release the dose reliably. Glass is widely used because it is chemically stable. Packaging therefore sits close to drug quality and supply security, which is why drugmakers qualify suppliers carefully.
Our analysis of the SCHOTT Pharma India name change
In our assessment, the SCHOTT Pharma India name change is a branding and governance step, not an operational event. Its significance is the signal about India’s role in the group, together with the capacity expansions the company mentions. Readers should watch for concrete announcements on plants and volumes, which would matter more than the name.
What is not disclosed in the SCHOTT Pharma India name change
- The size and location of the capacity expansions.
- Sales, profit or headcount figures.
- The group’s exact shareholding in the Indian company.
- Any change to registrations or certifications.
Risks and caveats
This article relies on a company announcement. Claims about being India’s only glass pre-fillable syringe maker are the company’s own. Market data are global estimates. This article is news reporting and not investment advice.
What to watch next after the SCHOTT Pharma India name change
- Details of the syringe and cartridge capacity expansion.
- New partnerships with pharma and biotech firms.
- Any regulatory or corporate filings reflecting the new name.
FAQ
Is SCHOTT Pharma India a new company?
No. It is the same company, formerly SCHOTT Poonawalla Private Limited, under a new name.
Has the ownership changed?
The company says ownership and management are unchanged.
When did the name take effect?
28 October 2026, according to the announcement.
How we reported this: we relied on the company announcement, the group website and the Acumen Research and Consulting reports cited above. Last updated 28 October 2026. This is news reporting and not advice.